Baidu
map

JACC: 心血管事件的独立预测因子--低密度脂蛋白胆固醇变化

2015-05-07 张旭栋译 MedSci原创

美国纽约大学医学院Sripal Bangalore博士等人探索了冠心病患者中,低密度脂蛋白胆固醇变化对于心血管结局的影响,其研究成果发表在4月份Journal of the American College of Cardiology期刊上。 背景:研究表明,通过使用他汀类药物降低低密度脂蛋白胆固醇(LDL-C),最终能够显著减少心血管事件发生。然而LDL-C水平变化对心血管结局的影响仍然未知。

美国纽约大学医学院Sripal Bangalore博士等人探索了冠心病患者中,低密度脂蛋白胆固醇变化对于心血管结局的影响,其研究成果发表在4月份Journal of the American College of Cardiology期刊上。

背景:研究表明,通过使用他汀类药物降低低密度脂蛋白胆固醇(LDL-C),最终能够显著减少心血管事件发生。然而LDL-C水平变化对心血管结局的影响仍然未知。

目的:本研究旨在评估LDL-C水平变化对心血管结局的影响。

方法:研究评估了参加了TNT(治疗新目标)试验且LDL-C<130mg/dl患有冠心病的患者,将其随机分配为接受阿托伐他汀80 mg /天与10mg/天两组,两组患者至少有过一次基线后LDL-C测量。通过不同的测量指标评估LDL-C的变化:标准差(SD),平均连续变异(ASV),变异系数,变异独立平均值,前2个参数作为主要测量参数。主要结局是冠脉事件,次要结局是心血管事件,死亡,心肌梗死卒中

结果:9572例患者中,与服用阿托伐他汀10mg/天患者相比,服用阿托伐他汀80mg/天患者其SD和ASV均显著降低(SD:12.52±7.43比12.03±9.70; P = 0.005; ASV:13.76±8.69比12.84±10.48; P <0.0001)。模型调整后,LDL-C变异每增加一个SD能够升高16%冠脉事件的风险(风险比[HR]:1.16;95%置信区间:1.10〜1.23; P <0.0001),升高11%心血管事件(HR:1.11; 95%CI:1.07〜1.15; P <0.0001),升高23%死亡率(HR:1.23;95%CI:1.14至1.34; P <0.0001) ,升高10%心肌梗死率(HR:1.10; 95%CI:1.02〜1.19; P =0.02),以及升高17%中风率(HR:1.17;95%CI:1.04〜1.31; P =0.01)。

结论:患有冠心病患者,LDL-C变化是心血管事件的独立预测因子。
 
原文出处:

Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH. Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes: Insights From the TNT Trial. Journal of the American College of Cardiology. 2015;65(15):1539-48.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853336, encodeId=e3051853336e4, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 03 13:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643361, encodeId=c68b16433616a, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Tue Oct 06 16:49:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310599, encodeId=22d81310599d4, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325024, encodeId=f0bf132502400, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424645, encodeId=c581142464558, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=)]
    2016-04-03 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853336, encodeId=e3051853336e4, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 03 13:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643361, encodeId=c68b16433616a, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Tue Oct 06 16:49:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310599, encodeId=22d81310599d4, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325024, encodeId=f0bf132502400, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424645, encodeId=c581142464558, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853336, encodeId=e3051853336e4, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 03 13:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643361, encodeId=c68b16433616a, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Tue Oct 06 16:49:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310599, encodeId=22d81310599d4, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325024, encodeId=f0bf132502400, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424645, encodeId=c581142464558, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853336, encodeId=e3051853336e4, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 03 13:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643361, encodeId=c68b16433616a, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Tue Oct 06 16:49:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310599, encodeId=22d81310599d4, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325024, encodeId=f0bf132502400, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424645, encodeId=c581142464558, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853336, encodeId=e3051853336e4, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 03 13:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643361, encodeId=c68b16433616a, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Tue Oct 06 16:49:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310599, encodeId=22d81310599d4, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325024, encodeId=f0bf132502400, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424645, encodeId=c581142464558, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat May 09 04:49:00 CST 2015, time=2015-05-09, status=1, ipAttribution=)]

相关资讯

我国发布冠心病、先心病和心律失常介入治疗大数据

第十八届全国介入心脏病学论坛(18th CHINA CARDIVOCASULAR INTERVENTION FORUM)于2015年4月24~26日在贵州省贵阳市举行。4月24日,论坛发布了冠心病、心律失常和先心病的介入治疗现状,现与读者分享。 冠心病介入治疗 从2010年开始,我国的冠心病介入诊疗质量控制工作已经进行了第5个年头。在这5年里我国的冠心病介入诊疗控制从松散到紧密,对

CIT 2015专访:钱菊英教授:中国冠心病的介入诊疗发展迅速

MedSci专访复旦大学附属中山医院心内科主任医师:钱菊英 MedSci:钱主任,您好!欢迎您来参加2015 CIT介入心脏病学大会。我们都知道您在冠心病的介入诊疗方面造诣颇深,您认为近些年中国冠心病的介入诊疗有什么突破性进展? 钱主任:近些年中国在冠心病的诊疗方面,无论是数量还是质量方面都取得了很大的进展。 首先,从数量方面看,根据霍勇教授统计的数据,201

临床医生如何正确理解和解读超声心动图报告

节段性室壁运动异常是否等同冠心病  超声心动图常被用于评价心脏的局部室壁运动异常来探查已知的或可疑的冠心病。缺血的心肌超声心动图表现为室壁运动减弱或消失或反常运动,心肌梗塞后或慢性心肌缺血引起心肌纤维化和疤痕形成,心肌节段回声密度增加,运动消失,舒张期室壁厚度也变薄。对于缺血性心脏疾病来说,这种节段性室壁运动异常是急性、慢性心肌缺血和心肌梗塞的共有特征。二维超声心动图显示的节段

Cell:血管紧张素受体——瞄准人类健康的隐形杀手

每三个美国人中就有一人罹患高血压,这一人类健康的隐形杀手可以导致冠心病、心力衰竭和中风等疾病。利用一种先进的X-射线分析技术,由来自美国、德国的科学家组成的一个研究小组,揭示出了人体中最重要的血压调控因子——血管紧张素受体AT1R的分子结构。他们的研究结果发表在4月23日的《细胞》(Cell)杂志上。南加州大学Dornsife文理学院首席研究员及教授Vadim Cherezov说,这项研究工作有可

Baidu
map
Baidu
map
Baidu
map